SEARCH

SEARCH BY CITATION

References

  • 1
    Lohse N, Hansen AB, Pedersen G et al. Survival of persons with and without HIV infection in Denmark, 1995–2005. Ann Intern Med 2007; 146: 8795.
  • 2
    Obel N, Thomsen HF, Kronborg G et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis 2007; 44: 16251631.
  • 3
    Friis-Moller N, Weber R, Reiss P et al. Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD Study. AIDS 2003; 17: 11791193.
  • 4
    Friis-Moller N, Sabin CA, Weber R et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 19932003.
  • 5
    Friis-Moller N, Reiss P, Sabin CA et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 17231735.
  • 6
    Sabin CA, Worm SW, Weber R et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the DAD Study: a multi-cohort collaboration. Lancet 2008; 371: 14171426.
  • 7
    DAD Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22: F17F24.
  • 8
    Lohse N, Hansen AB, Jensen-Fangel S et al. Demographics of HIV-1 infection in Denmark: results from the Danish HIV Cohort Study. Scand J Infect Dis 2005; 37: 338343.
  • 9
    Obel N, Engsig F, Rasmussen LD et al. Cohort profile: The Danish HIV Cohort Study. Int J Epidemiol 2008; doi:DOI: 10.1093/ije/dyn192.
  • 10
    Frank L. Epidemiology. When an entire country is a cohort. Science 2000; 287: 23982399.
  • 11
    Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999; 46: 263268.
  • 12
    Glynn RJ, Schneeweiss S, Sturmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006; 98: 253259.
  • 13
    Abildstrom SZ, Rasmussen S, Madsen M. Changes in hospitalization rate and mortality after acute myocardial infarction in Denmark after diagnostic criteria and methods changed. Eur Heart J 2005; 26: 990995.
  • 14
    Hughes MD, Williams PL. Challenges in using observational studies to evaluate adverse effects of treatment. N Engl J Med 2007; 356: 17051707.
  • 15
    Bernasconi E, Boubaker K, Junghans C et al. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2002; 31: 5055.
  • 16
    Jacobson DL, Knox T, Spiegelman D, Skinner S, Gorbach S, Wanke C. Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women. Clin Infect Dis 2005; 40: 18371845.
  • 17
    Moyle GJ, Baldwin C, Langroudi B, Mandalia S, Gazzard BG. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr 2003; 33: 2228.
  • 18
    Moyle GJ, Sabin CA, Cartledge J et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006; 20: 20432050.
  • 19
    Podzamczer D, Ferrer E, Sanchez P et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr 2007; 44: 139147.
  • 20
    John M, McKinnon EJ, James IR et al. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J Acquir Immune Defic Syndr 2003; 33: 2933.
  • 21
    Carr A, Workman C, Smith DE et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 2002; 288: 207215.
  • 22
    Berenguer J, Perez-Elias MJ, Bellon JM et al. Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy-naïve HIV-infected patients: results from a large multicenter observational cohort. J Acquir Immune Defic Syndr 2006; 41: 154159.
  • 23
    Petri H, Urguhart J. Channeling bias in the interpretation of drug effects. Stat Med 1991; 10: 577581.
  • 24
    Cutrell A, Brothers C, Yeo J, Hernandez J, Lapierre D. Abacavir and the potential risk of myocardial infarction. Lancet 2008; 371: 1413.
  • 25
    Sabin CA, D'Arminio Monforte A, Friis-Moller N et al. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. Clin Infect Dis 2008; 46: 11011110.
  • 26
    Phillips E, Mallal S. Drug hypersensitivity in HIV. Curr Opin Allergy Clin Immunol 2007; 7: 324330.
  • 27
    Zethelius B, Berglund L, Sundstrom J et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008; 358: 21072116.